Verrica Pharmaceuticals Announces Resubmission of New Drug Application for VP-102 for the Treatment of Molluscum Contagiosum
Potential First FDA-approved Therapy for Treatment of Molluscum Contagiosum
Prevalence of Over 6 Million Molluscum Contagiosum Patients in the U.S. Alone
Related news for (VRCA)
- Verrica Pharmaceuticals Announces That Development Partner, Torii Pharmaceutical, Receives Approval for YCANTH® (TO-208) in Japan for the Treatment of Molluscum Contagiosum
- 24/7 Market News Snapshot 19 September, 2025 – Verrica Pharmaceuticals Inc. Common Stock (NASDAQ:VRCA)
- Spider Silk & Crypto-Powered Rebrands Signal a New Investor Web
- Verrica Pharmaceuticals Reports Quarterly 2025 Financial Results
- Verrica Pharmaceuticals Reports Strong Demand-Led Growth in YCANTH® Dispensed Applicator Units in First Quarter 2025